首页> 外文期刊>Bone marrow transplantation >Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
【24h】

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.

机译:成年患者费城染色体阳性急性淋巴细胞白血病的清髓同种异体造血干细胞移植:全身照射和慢性移植物抗宿主病的重要作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Disease-free survival in Philadelphia chromosome-positive ALL (Ph + ALL) is very poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently considered the only procedure with curative potential. To identify factors affecting transplant outcome, we analyzed the data from 197 Ph + ALL patients aged 16 years or older who had undergone allo-HSCT. The 5-year survival rates were 34% for patients in first complete remission (CR), 21% for those in second or subsequent CR, and 9% for those with active disease (P < 0.0001). Multivariate analysis showed four pre-transplant factors as significantly associated with better survival: younger age, CR at the time of transplantation, conditioning with total body irradiation, and HLA-identical sibling donor (P < 0.0001, P < 0.0001, P = 0.0301, P = 0.0412, respectively). Severe acute GVHD increased the risk of treatment-related mortality (TRM) without diminishing the risk of relapse, whereas chronic GVHD reduced the risk of relapse without increasing the risk of TRM. Thus, patients who developed extensive chronic GVHD had better survivals (P = 0.0217), and those who developed grade III-IV acute GVHD had worse survivals (P = 0.0023) than did the others.
机译:费城染色体阳性ALL(Ph + ALL)的无病生存期非常差,同种异体造血干细胞移植(allo-HSCT)目前被认为是唯一具有治愈潜力的方法。为了确定影响移植结果的因素,我们分析了来自197名Ph + ALL年龄在16岁或以上的allo-HSCT患者的数据。首次完全缓解(CR)患者的5年生存率分别为34%,第二次或后续CR患者的21%和活动性疾病患者的9%(P <0.0001)。多因素分析显示,移植前的四个因素与更好的生存率显着相关:年龄较小,移植时的CR,全身照射条件以及与HLA相同的同胞供体(P <0.0001,P <0.0001,P = 0.0301, P分别为0.0412)。严重的急性GVHD在不降低复发风险的情况下增加了与治疗相关的死亡率(TRM)的风险,而慢性GVHD在不增加TRM风险的情况下降低了复发的风险。因此,发生广泛性慢性GVHD的患者存活率更高(P = 0.0217),而发生III-IV级急性GVHD的患者存活率则较其他患者差(P = 0.0023)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号